Sumatriptan
FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Migraine disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective serotonin (5ht1) agonists
- FDA pharmacologic class
- Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
NCT00434083 · start 2004-07
Registered record
- Registry ID
- NCT00434083
- Conditions
- Migraine Headaches
- Interventions
- sumatriptan; naproxen sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-01
- Enrolment
- 1,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadachesInterventionsumatriptan; naproxen sodiumPhasePhase 3Registry statusCompletedSumatriptan Succinate 100 mg Tablets Under Fasting Conditions
NCT00847405 · start 2003-03
Registered record
- Registry ID
- NCT00847405
- Conditions
- Healthy
- Interventions
- Sumatriptan Succinate; Imitrex®
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2003-03
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSumatriptan Succinate; Imitrex®PhasePhase 1Registry statusCompletedSumatriptan and Naratriptan Pregnancy Registry
NCT01059604 · start 2001-12
Registered record
- Registry ID
- NCT01059604
- Conditions
- Migraine Disorders
- Interventions
- Sumatriptan; Naratriptan; Sumatriptan-naproxen combination
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2001-12
- Completion
- 2013-04
- Enrolment
- 868
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine DisordersInterventionSumatriptan; Naratriptan; Sumatriptan-naproxen combinationPhaseNot recordedRegistry statusCompletedDrug Use Investigation for IMIGRAN Tablet
NCT01376141 · start 2001-09
Registered record
- Registry ID
- NCT01376141
- Conditions
- Migraine Disorders
- Interventions
- Sumatriptan
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2001-09
- Completion
- 2005-11
- Enrolment
- 3,571
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine DisordersInterventionSumatriptanPhaseNot recordedRegistry statusCompletedMK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
NCT00897104 · start 1995-08
Registered record
- Registry ID
- NCT00897104
- Conditions
- Migraine Headache
- Interventions
- rizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1995-08
- Completion
- 1996-09
- Enrolment
- 933
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadacheInterventionrizatriptan benzoate (MK0462); Comparator: sumatriptan; Comparator: PlaceboPhasePhase 3Registry statusCompleted